Wikipedia -WSS

Wikipedia

author：entertainment 2025-09-02 08:10:12 - browse：3741

Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： How to pay for weight loss drugs and save Medicare

knowledge

WSS

Oak Street deal isn't the answer to health care's woes

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Supreme Court to hear if Covid misinformation is protected speech

ALS treatment from Biogen, Ionis fails in study

As biotech industry slumps, bioscience job market is upside down

STAT series 'Denied by AI' wins major journalism prizes

entertainment

Wikipedia

Wikipedia

Cancer drug shortages should be causing more outrage

STAT series 'Denied by AI' wins major journalism prizes

FDA approval of Sarepta Duchenne genetic therapy gives me hope

ALS treatment from Biogen, Ionis fails in study

Malaria cases in Florida and Texas: Here’s what you need to know

WuXi Biologics beefs up its lobbying operation

In age of alternative facts, a scholarly course on calling out crap

Cherokee Nation medical school graduates its first class

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

hotspot

The White House hikes tariffs on plastic syringes made in China

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Takeda, Janssen join wearable maker to measure scratching

Despite FDA concern, risk that CAR

Lilly’s weekly insulin works as well as daily products, new studies show

CDC director unscathed in first congressional testimony

focus

knowledge

explore

leisure time